Genomic Expression Inc

Exponentially scalable RNA AI platform for Next Generation Cures. By analyzing RNA, we can detect disease, monitor health, and design cures

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Boston, MA, US
  • Currency USD
  • Founded July 2017
  • Employees 5
  • Incorporation Type C-corp
  • Website genomicexpression.com

Company Summary

RNA AI Powered Platform for Next Generation Cures - by analyzing RNA, we can detect disease, monitor health and design the next generation cures.

Our RNA AI Platform (Platform as a Service) is saving lives today and will bend the cost and time curve for drug discovery and development in the future. We are a biological software company enabling RNA AI at scale.

OneRNA® Immediate Impact drives adoption: Provide new hope for all (100% diagnostic yield) of the 50-80% of cancer patients who do not respond to their current treatments. Specific payor code for RNA-seq diagnostics $3,000/test our margins are 90%.

CLIA-validated in breast cancer and ovarian cancer, ready for commercial launch - No FDA approval required

Team

  • MSc, BA Business, company builder with a mission to improve health and sustainability. Advised biotech companies as well as the Danish Ministry of Foreign Affairs, bringing in +$1B deals to Danish Biotech companies. Won numerous prices, awards and raised $8M in grants. Worked at Novo Nordisk invented, developed & commercialized products worldwide.

    Founded Genomic Expression with her brother when their parents got diagnosed with cancer.

  • Dr. Morten L. Pedersen, CSO and co-founder. Post doc in genetics from Copenhagen University. Serial entrepreneur and inventor of groundbreaking novel enzymatic nucleic acid chemistries.
    Have filed and issued patents in USA, Europe, and Canada. Worked at The Kennedy Institute in Copenhagen, where he also conducted his graduate thesis investigating the phenomenon of genetic imprinting in Beckwith–Wiedemann syndrome and Angelman syndrome.

  • Jesper Zeuthen
    CMO, PhD

    Dr Jesper Zeuthen holds a degree in molecular biology from the University of Copenhagen and a D.Sc. in biology. He has held positions at the Karolinska Institute, Novo Nordisk, and the Danish Cancer Society. Jesper co-founded many biotech companies, notably Genmab (market cap $14 Billion).
    His goal is to "cure" cancer using all the tools in the toolbox, from better drugs and pioneering immune therapy to early detection

  • Morten has been instrumental in developing normalization algorithms  (AI) implemented in Genomic Expression’s analysis pipeline. He is a serial entrepreneur in the fields of Big Data Mining, Analytics, Artificial Intelligence, and Machine Learning. He was the CTO at TARGET, a business intelligence company, the world’s largest BI vendor for companies using Microsoft Dynamics.

  • COO/Advisor

    Postdoc MIT. Founder of BioTrove, a multiplex PCR Platform (1st Generation RNA expression) that was sold to ThermoFisher. Tanya has been instrumental on the wetlab and drylab side, bridging the two domains. Her deep understanding of the regulatory requirements for an assay to make it through the regulatory hurdles helped shape the successful validation plans Genomic Expression executed. 

Advisors

  • Duane Morris LLP
    Lawyer
    Unconfirmed
    FullSky Partners
    Unconfirmed

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free